Xudong Zeng

Xudong Zeng

Auto-generated profile, based on publicly available information

Xudong Zeng

Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2023 in Communications Biology
Verified
Journal Article
Open access
PDF file
MLMengmeng Lin
Mengmeng Lin
XZXudong Zeng
Xudong Zeng
YDYinkai Duan
Yinkai Duan
ZYZinan Yang
Zinan Yang
YMYuanyuan Ma
Yuanyuan Ma
XLXiang Liu
Xiang Liu
SARS-CoV-2 poses an unprecedented threat to the world as the causative agent of the COVID-19 pandemic. Among a handful of therapeutics developed for the prevention and treatment of SARS-CoV-2 infection, ensitrelvir is the first noncovalent and nonpeptide oral inhibitor targeting the main protease (Mpro) of SARS-CoV-2, which recently received emergency regulatory approval in Japan. Here we determined a 1.8-Å structure of Mpro in complex with ensitrelvir, which revealed that ensitrelvir targets the substrate-binding pocket of Mpro, specifically recognizing its S1, S2, and S1' subsites. Further, our comprehensive biochemical and structural data have demonstrated that even though ensitrelvir and nirmatrelvir (an FDA-approved drug) belong to different types of Mpro inhibitors, both of them remain to be effective against Mpros from all five SARS-CoV-2 variants of concern, suggesting Mpro is a bona fide broad-spectrum target. The molecular mechanisms uncovered in this study provide basis for future inhibitor design.

4 August 2026 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MLMengmeng Lin
Mengmeng Lin
XZXudong Zeng
Xudong Zeng
YXYunjie Xiao
Yunjie Xiao
MZMeng Zhang
Meng Zhang
DLDong Li
Dong Li
DWDeping Wang
Deping Wang